Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
During 4 weeks of treatment with clorgyline, a selective MAO-A inhibitor, platelet monoamine oxidase (MAO) activity was unchanged. During a similar 4-week crossover treatment period with pargyline, a selective MAO-B inhibitor, platelet MAO activity was essentially completely inhibited in the same individuals. The differential effects of the two drugs on platelet MAO, which consists exclusively of the MAO-B form, suggests that the in vitro selectivity of clorgyline, and possibly of pargyline, on MAO-A and MAO-B may be maintained in vivo during long-term administration in man. Reductions in blood pressure, heart rate, and plasma amine oxidase activity were generally similar in magnitude during treatment with both drugs, however, suggesting that either these effects are nonspecific consequences of both MAO-A and MAO-B inhibition, or that pargyline also inhibited MAO-A activity.
D001792:Blood Platelets / Q000201:enzymology; D003010:Clorgyline / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008995:Monoamine Oxidase / Q000097:blood; D008996:Monoamine Oxidase Inhibitors; D010293:Pargyline / Q000494:pharmacology*; D011437:Propylamines / Q000494:pharmacology*; D012642:Selegiline / Q000494:pharmacology
D008996:Monoamine Oxidase Inhibitors; D011437:Propylamines; D012642:Selegiline; D010293:Pargyline; D008995:Monoamine Oxidase; D003010:Clorgyline